{"sourcedb":"DevicePMAs@therightstef","sourceid":"P860004_S066","text":"Approval for the intrathecal administration of prialt (ziconotide).  The device, as modified, will be marketed under the trade name synchromed implantable infusion system and is indicated for the chronic intrathecal infusion of preservative-free ziconotide sterile solution for the management of severe, chronic pain.","project":"consensus_PMA_Age_Indications"}